Medicina
Departamento
Orlando Immunology Center
Orlando, Estados UnidosPublicaciones en colaboración con investigadores/as de Orlando Immunology Center (7)
2020
2018
-
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
The Lancet HIV, Vol. 5, Núm. 5, pp. e211-e220
-
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
The Lancet HIV, Vol. 5, Núm. 4, pp. e162-e171
2016
2006
-
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment - Experienced, HIV-infected individuals: Recent data and consensus recommendations
HIV Clinical Trials, Vol. 7, Núm. 2, pp. 86-96
-
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
Lancet, Vol. 368, Núm. 9534, pp. 476-482